Albireo Recognizes PFIC Awareness Day 2021

By adminOctober 5, 2021Global News Feed

BOSTON, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, joins the PFIC Advocacy and Resource Network (PFIC Network) in recognition of PFIC Awareness Day 2021, a global effort to support patients and families affected by progressive familial intrahepatic cholestasis (PFIC). Established in 2019, PFIC Awareness Day aims to highlight the impact of this disease on patients and families, and to call for new levels of support, including research, advocacy, education and opportunities to connect and share information.

Read more:
Albireo Recognizes PFIC Awareness Day 2021

Scopus BioPharma to Present at the LD Micro Main Event

By adminOctober 5, 2021Global News Feed

Scopus to present on the recent launch of Duet Therapeutics, its wholly-owned subsidiary focused on immuno-oncology

Read more:
Scopus BioPharma to Present at the LD Micro Main Event

Celsion Corporation Adds Key Resources to its Vaccine Development Initiative and Clinical Trial Capabilities

By adminOctober 5, 2021Global News Feed

LAWRENCEVILLE, N.J., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announces the strengthening of its management team with a new hire and a promotion in its vaccine development program, and the hiring of a veteran clinical trial project manager for its Phase II GEN-1 immunotherapy study in advanced ovarian cancer. These changes all are effective immediately and are as follows:

Link:
Celsion Corporation Adds Key Resources to its Vaccine Development Initiative and Clinical Trial Capabilities

CohBar to Present at H.C. Wainwright 5th Annual NASH Investor Conference

By adminOctober 5, 2021Global News Feed

MENLO PARK, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Dr. Joseph Sarret, will present a company overview at the H.C. Wainwright 5th Annual NASH Investor Conference, being held virtually on October 12, 2021.

View post:
CohBar to Present at H.C. Wainwright 5th Annual NASH Investor Conference

TCR² Therapeutics Presents Preclinical Data on IL-15 Enhanced TRuCs at AACR Virtual Special Conference on Tumor Immunology & Immunotherapy

By adminOctober 5, 2021Global News Feed

CAMBRIDGE, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced the e-poster presentation of new preclinical data at the American Association for Cancer Research (AACR) Virtual Special Conference on Tumor Immunology and Immunotherapy, taking place October 5-6, 2021. The e-poster titled “Expression of an IL-15 Receptor Fusion Protein Enhances the Persistence of TRuC-T Cells” highlights preclinical data on the Company’s proprietary mesothelin-directed T Cell Receptor Fusion Construct (TRuC®) T cells that express IL-15-based enhancements as a strategy for improving T cell persistence. The co-expression of these IL-15 enhancements enriched for naïve and central memory T cells, upregulated the stemness-associated transcription factor TCF-1 and increased TRuC-T cell proliferation upon repeated stimulation with mesothelin-expressing cancer cell lines. In addition, IL-15 promoted the survival of TRuC-T cells in the absence of T cell receptor (TCR) or exogenous cytokine stimulation. In a mesothelioma xenograft mouse model, IL-15 co-expression resulted in a higher number of TRuC-T cells in the tumor and significantly increased their persistence in peripheral blood. The administration of a single dose of IL-15 enhanced TRuC-T cells cleared tumors in all mice and fully protected them from tumor rechallenge.

See the original post:
TCR² Therapeutics Presents Preclinical Data on IL-15 Enhanced TRuCs at AACR Virtual Special Conference on Tumor Immunology & Immunotherapy

AXIM® Biotechnologies Appoints Senior DED Expert Dr. Laura Periman to its Medical Advisory Board

By adminOctober 5, 2021Global News Feed

Dr. Periman Joins Chairman Joseph Tauber as Advisory Board’s Second Member Dr. Periman Joins Chairman Joseph Tauber as Advisory Board’s Second Member

See the original post here:
AXIM® Biotechnologies Appoints Senior DED Expert Dr. Laura Periman to its Medical Advisory Board

Levitee Labs Publishes First Revenue Figures for August 2021

By adminOctober 5, 2021Global News Feed

VANCOUVER, British Columbia, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Levitee Labs Inc. (the "Company" or "Levitee Labs”) (CSE: LVT), an integrative wellness company with a diversified portfolio of healthcare and wellness assets, is pleased to publish revenue figures for the month of August 2021. On a consolidated basis, the Company has recorded (unaudited) revenue of $893,863 for the month of August.

See the rest here:
Levitee Labs Publishes First Revenue Figures for August 2021

Weblink Instructions for the Annual Meeting of Shareholders of Zivo Bioscience, Inc.

By adminOctober 5, 2021Global News Feed

KEEGO HARBOR, Mich., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Zivo Bioscience, Inc. (NASDAQ: ZIVO, ZIVOW) (“ZIVO” and the “Company”), a biotech/agtech R&D company engaged in the development and commercialization of therapeutic, medicinal and nutritional product candidates originally derived from proprietary algal cultures, today issues a notice to its shareholders concerning the annual shareholder meeting.

View post:
Weblink Instructions for the Annual Meeting of Shareholders of Zivo Bioscience, Inc.

SEngine Precision Medicine and Gustave Roussy Announce Plan to Launch PARIS® Test in Europe

By adminOctober 5, 2021Global News Feed

Prospective joint venture will accelerate precision medicine in Europe by harnessing innovations in high-throughput drug testing, 3D tumor cell culture, and AI analytics established at SEngine Precision Medicine to identify the best personalized therapeutic matches for patients Prospective joint venture will accelerate precision medicine in Europe by harnessing innovations in high-throughput drug testing, 3D tumor cell culture, and AI analytics established at SEngine Precision Medicine to identify the best personalized therapeutic matches for patients

Original post:
SEngine Precision Medicine and Gustave Roussy Announce Plan to Launch PARIS® Test in Europe

Strongbridge Biopharma plc Announces Completion of Acquisition by Xeris Pharmaceuticals, Inc.

By adminOctober 5, 2021Global News Feed

DUBLIN, Ireland and TREVOSE, Pa., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “Company” or “Strongbridge”) today announced that the High Court of Ireland (the "Court") has approved the previously announced proposed acquisition of Strongbridge by Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) (“Xeris”) by means of a scheme of arrangement (the "Scheme") under Chapter 1 of Part 9 of the Irish Companies Act 2014 (the "Act").

Visit link:
Strongbridge Biopharma plc Announces Completion of Acquisition by Xeris Pharmaceuticals, Inc.